Lung Cancer

Compared to osimertinib alone, first-line treatment with amivantamab plus lazertinib was also shown to improve progression-free survival and have an increased duration of response.

Compared to placebo plus chemotherapy, nivolumab plus chemotherapy had also improved event-free survival and both pathological complete response and major pathologic response rates.

Compared to chemotherapy alone, amivantamab plus chemotherapy had a better objective response rate and prolonged progression-free survival and overall survival.

The novel combination met the co-primary endpoints of progression-free survival and overall survival during the CheckMate -901 trial, also demonstrating sizeable improvement in objective response.

Not only did taletrectinib shrink tumors in 92% of patients who were tyrosine kinase inhibitor -naïve, but 89.5% of patients continued to respond to treatment at 12 months.

The fast pace of information can make it difficult to efficiently apply data to care.

The statistically significant and clinically meaningful improvement in disease-free survival is “practice-changing” and may represent a “paradigm shift” in treatment, according to experts.

Integrating immunotherapies will continue to improve patient outcomes and quality of life.

PLCOm2012 uses additional parameters to predict the risk of lung cancer and was found more effective when identifying both Indigenous and non-Indigenous individuals with lung cancer.

Pembrolizumab (Keytruda) gains its sixth approval in non–small cell lung cancer (NSCLC), with the latest indication in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a monotherapy for the post-surgical adjuvant treatment of patients with resectable NSCLC.

Mental health treatment may be necessary when SAEs occur.

Trial data bolster the role of nivolumab and nivolumab-based combinations in both early and metastatic stages of multiple cancer types, especially in patient groups with high unmet needs.

Encorafenib (Braftovi; Pfizer Inc) and binimetinib (Mektovi; Pfizer Inc) approved for the treatment of patients with metastatic non-small cell lung cancer who harbor a BRAF V600E mutation.

The MARIPOSA study evaluated amivantamab-vmjw (Rybrevant; Janssen Pharmaceutical) in combination with lazertinib compared to osimertinib and compared to lazertinib monotherapy in the first-line treatment of EGFR-mutated non–small cell lung cancer.

Nivolumab has also demonstrated efficacy in immunotherapy-based combinations for the treatment of certain types of melanoma and bladder cancers.

In many countries, trastuzumab deruxtecan is the only HER2-targeted therapy approved for patients with this HER2–mutant metastatic non-small cell lung cancer.

Moderna has advanced 6 programs into late-stage development, including for respiratory conditions, latent and other viruses, oncology, and rare diseases.

Investigators found an approximately 23% decrease in overall cancer incidence in April 2020, specifically for breast, colon, rectal, head and neck cancers, as well as melanoma and endocrine cancer diagnoses.

Sotorasib (Lumakras) plus carboplatin and pemetrexed shows promise in the first line treatment of advanced non–small cell lung cancer.

Compared to chemotherapy alone, the combined nivolumab and ipilimumab treatment more than tripled the overall survival rate at 6 years in patients with PD-L1 expression <1%.

The study met its primary endpoint of progression-free survival, and overall survival is continuing to be evaluated.

Patients who received amivantamab plus chemotherapy or amivantamab without chemotherapy presented better outcomes compared to chemotherapy alone.

If approved, alectinib would be the only anaplastic lymphoma kinase inhibitor to show reductions in risk of recurrence or death for those with early-stage lung cancer.

Patients with cancer and survivors of cancer that had engaged in administrative tasks to effectively estimate costs or pay for care was associated with an 18% increase in cost-related treatment delays or treatment nonadherence.

The supplemental biologics license application for amivantamab-vmjw (Rybrevant) is supported by data from the phase 3 PAPILLON trial, evaluating the efficacy and safety of the drug in combination with chemotherapy for those with non–small cell lung cancer.

Investigators found that artificial intelligence chatbots did not consistently provide recommendations for cancer treatment that correspond with NCCN guidelines.

The digital cessation platform is the first FDA-cleared OTC device to help individuals quit smoking tobacco.

In the study, investigators incorporated data from electronic health records and social determinants of health into the model to determine the likelihood in delays when starting cancer therapy.

Based on results from a trial of repotrectinib in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer, the FDA accepted the New Drug Application and set a Prescription Drug User Fee Act goal date of November 27, 2023.

Though an association was found between depression and anxiety and lung cancers, there were no connections found to overall, breast, prostate, colorectal, and alcohol-related cancers.